LATEST NEWS
Favorable End-of-Phase 2 meeting with U.S. FDA for [18F]FAPI-74 for GI cancers Primary and secondary endpoints met Alignment with FDA on study design to advance [...]
LATEST NEWS
Favorable End-of-Phase 2 meeting with U.S. FDA for [18F]FAPI-74 for GI cancers Primary and secondary endpoints met Alignment with FDA on study design to advance [...]